Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: principles (564), values (295)

Sunitinib v1

Description: Chemotherapy Protocol SARCOMA Gastro-Intestinal Stromal Tumour (GIST) Regimen Sunitinib GIST-Sunitinib Indication Sunitinib is recommended as a possible treatment for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Sunitinib-v1.pdf

ImatinibChronic

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Regimen IMATINIB (chronic phase) • CML – Imatinib (chronic phase) Indication • As the preferred first-line treatment for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/ImatinibChronic.pdf

ImatinibAccelerated

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Regimen IMATINIB (accelerated phase) • CML - Imatinib (accelerated phase) Indication • As the preferred option for the treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/ImatinibAccelerated.pdf

Child protection and safeguarding - patient information

Description: Child protection and safeguarding Information for parents, carers and guardians Child protection at Southampton Children’s Hospital The medical management of
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Child-protection-and-safeguarding-2197-PIL.pdf

Neuroendocrine-Sunitinib Ver 1

Description: Chemotherapy Protocol NEUROENDOCRINE SUNITINIB Regimen Neuroendocrine - Sunitinib Indication The 1st, 2nd or 3rd line treatment of pancreatic neuroendocrine carcinomas that are
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Neuroendocrine-Sunitinib-Ver-1.pdf

BRC Research Theme Lead JD and PS

Description: National Institute for Health Research Southampton Biomedical Research Centre : NIHR BRC Theme Lead National Institute for Health Research (NIHR)
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-Research-Theme-Lead-JD-and-PS.doc

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficac
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Quality Committee ToR March 2026

Description: Quality Committee Terms of Reference Date Issued: 10 March 2026 Review Date: January 2027 Document Type: Terms of Reference Version: 8 Contents
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Quality-Committee-ToR-March-2026.pdf

AmB - Cytarabine(3000)

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA AmB- CYTARABINE (3000mg/m2) Ambulatory Regimen This regimen is for AMBULATORY CARE pathway use only Regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AmB-Cytarabine-3000.pdf

Preventing infection - patient information

Description: Preventing infection Information for patients 3 At University Hospital Southampton NHS Foundation Trust (UHSFT) we take infection preve
Url: /Media/UHS-website-2019/Patientinformation/Visitinghospital/Preventinginfection-patientinformation.pdf

171 to 180 of 427

Previous … 16 17 18 19 20 … Next